REC Publications | Blog
NUEVO FI: 3,792
- Dr. Juan Sanchis
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Estimados lectores:
Nos alegra hacerte partícipe del dato del factor de impacto (FI) de Rev Esp Cardiol que se acaba de publicar en la última edición del Journal Citation Reports. Recibimos con entusiasmo la puntuación de 3,792 que supone un progreso notable en relación con los datos de factor de impacto previos (FI 2011: 2,530 – FI 2012: 3,204 – FI 2013: 3,342), y coloca a nuestra revista como líder indiscutible de la publicación científica en español, no solo entre las publicaciones médicas, sino en todas las disciplinas.
CoreValve US Pivotal Trial: Resultados a dos años
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Introduction
The randomized CoreValve trial demonstrated that transcatheter aortic valve replacement (TAVR) resulted in significantly lower mortality compared with surgical AVR at 1 year in patients who were at increased risk for surgery. Longer-term outcomes following TAVR with the self- expanding CoreValve are necessary to further validate this survival advantage.
AATAC-AF: Ablación vs amiodarona para el tratamiento de la fibrilación auricular persistente en pacientes con insuficiencia cardiaca y un dispositivo implantable
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Introduction
Catheter ablation (CA) represents a valid treatment option in patients with drug-refractory symptomatic atrial fibrillation (AF). The majority of catheter ablation trials have mainly enrolled patients with preserved LVEF and paroxysmal AF. However, a significant number of patients with AF also have heart failure (HF) and rhythm control with antiarrhythmic drugs has not shown satisfactory results in randomized trials both in patients with or without HF. Whether CA is superior to Amiodarone (AMIO) for the treatment of persistent AF in patients with HF is unknown.
PROMISE: Evaluación económica
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Introduction
The PROMISE trial is an NHLBI-funded randomized comparative effectiveness trial that compared anatomic testing (≥ 64 detector CT angiography) versus functional testing (exercise ECG, stress nuclear, or stress echocardiography) as the initial diagnostic test in patients with new onset symptoms suspicious for coronary artery disease in whom clinicians required diagnostic testing for further evaluation. An economic substudy was conducted to assess economic outcomes and cost effectiveness from a US societal perspective.
ERICCA: Precondicionamiento isquémico y pronóstico en pacientes a los que se les va a realizar cirugía de revascularización coronaria
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Introduction
There is a need of cardiac protective strategies for high risk patients undergoing cardiac surgery. Remote ischemic conditioning (RIC) supposes a simple non-invasive and low-cost intervention that may improve long-term clinical outcomes in this setting.
DEFLECT III: Evaluación del dispositivo de protección embólica TriGuard en TAVI
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Introduction
Clinical stroke after TAVR is frequent (4-7% at 30 days in RCTs), generally under-reported (17% after SAVR when evaluated by neurologist), confers 3- to 9-fold increased risk of mortality and 50% occurs peri-procedural. Silent stoke affects 58-100% of patients and are associated with neurocognitive decline, dementia and stroke.
Experiencia inicial de la reparación valvular mitral transcatéter
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Introduction
Degenerative MR is common, affecting ~600,000 persons in the U.S. Surgery is the standard of care, and is indicated for patients with symptoms or LV dysfunction. However, there are patients in whom the risk of surgery is prohibitive. The Mitraclip system received commercial approval in October 24, 201, being indicated for symptomatic patients with primary MR ≥3 and prohibitive surgical risk. Our objective was to analyze and report the initial commercial experience with the MitraClip System in the U.S.
PARTNER 1: Resultados a 5 años del implante percutáneo de válvula aórtica en pacientes con estenosis aórtica y alto riesgo quirúrgico
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Published in The Lancet.
Introduction
The Placement of Aortic Transcatheter Valves (PARTNER) trial showed that mortality at 1 year, 2 years, and 3 years is much the same with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) for high-risk patients with aortic stenosis. We report here the 5-year outcomes.
Ablación de la fibrilación auricular durante la cirugía mitral
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Published in NEJM
Introduction
Among patients undergoing mitral-valve surgery, 30 to 50% present with atrial fibrillation, which is associated with reduced survival and increased risk of stroke. Surgical ablation of atrial fibrillation has been widely adopted, but evidence regarding its safety and effectiveness is limited.
LEGACY: Efecto de la pérdida de peso en el control del ritmo en pacientes con fibrilación auricular
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Published in JACC
Introduction
Obesity and atrial fibrillation (AF) are dual epidemics that frequently coexist. Weight-loss reduces AF burden; however, whether this is sustained, has a dose effect or is influenced by weight-fluctuation is not known. The aim was to evaluate the long-term impact of weight-loss and weight-fluctuation on rhythm control in obese individuals with atrial fibrillation.
Página 46 de 77
Vídeos del Editor
¿Quieres ver los vídeos del editor de REC Publications?
Encuéntralos aquí
Participa
A lo largo de los años, el blog de la SEC se ha revelado como un instrumento ideal para mantenerse al día de las novedades más importantes que se publican en las revistas científicas internacionales y estimular el debate entre los cardiólogos. Por ello, Cardiología hoy es un foro abierto a la participación de todos los profesionales de salud. Si quieres escribir un artículo...